TITLE

Efficacy and Safety of Latanoprost for Glaucoma Treatment: A Three-Month Multicentric Study in India

AUTHOR(S)
Thomas, Ravi; Parikh, Rajul; Sood, Devendra; Vijaya, L.; Sekhar, G. Chandra; Sood, Narendra N.; Baskaran, M.; Prasad, K. Kalyani
PUB. DATE
March 2005
SOURCE
Indian Journal of Ophthalmology;Mar2005, Vol. 53 Issue 1, p23
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: To evaluate the short-term efficacy and safety of 0.005% topical latanoprost in Indian eyes. Design: Prospective non-randomised open-label multicentric trial. Methods: One hundred and fifty patients with ocular hypertension (OHT), primary open-angle, pseudoexfoliation or pigmentary glaucoma were enrolled at four centers. Each center contributed at least 20 patients. Following baseline measurements, 0.005% latanoprost was applied topically once daily in the evening for three months. Patients were examined at 2, 6 and 12 weeks. The primary outcome measure was mean intraocular pressure (IOP) reduction. The mean diurnal variation of IOP (difference between highest and lowest IOP) at baseline and at 12-weeks was compared. Results: One hundred and thirty of 150 enrolled patients completed the study. One randomly selected eye of each patient was included for analysis. At three months, latanoprost reduced the mean IOP from 24.9 ( 3.16) mmHg at baseline to 16.10 ( 2.7) mmHg, a reduction of 35.25%. 83% had a reduction in IOP of > 25%. The IOP reduction was maintained throughout the study period, and was not affected by gender or age of the patient. One eye did not show any response to the drug. Daytime diurnal variation of IOP was reduced from 4.5 to 2.9 mmHg. 20 patients had conjunctival hyperemia. Six patients had side effects requiring withdrawal from the study. Conclusions: In this short-term multicentric study, latanoprost effectively reduced IOP and stabilised the diurnal curve in Indian eyes. There were no clinically significant ocular or systemic adverse effects.
ACCESSION #
18102239

 

Related Articles

  • Adherence in Glaucoma Therapy. Hahn, Steven R. // Review of Optometry;8/15/2007 Part 2 of 2, Vol. 144, p20 

    The article discusses the adherence in glaucoma therapy in the U.S. Numerous studies have demonstrated that patients consistently are under report. A meta analysis of 86 studies revealed that patient consistently overestimated adherence to treatment compared to non-self-report methods of...

  • Aids to Glaucoma Compliance.  // Review of Optometry;8/15/2006, Vol. 143 Issue 8, p92 

    The article presents questions and answers related to glaucoma therapy. An eye specialist has inquired about the problem with his patient who is not compliant with his glaucoma medication. It was stated that many of such patients continue to be non-compliant for various reasons. Many eye...

  • Retrospective single-surgeon study suggests ALT superior to SLT. Ford, Bryce; Piltz-Seymour, Jody R. // Ophthalmology Times;4/1/2006, Vol. 31 Issue 7, p64 

    The article presents a single-surgeon study of glaucoma patients with uncontrolled IOP on maximally tolerated medical therapy. Argon laser trabeculoplasty (ALT) was associated with a greater IOP-lowering effect than selective laser trabeculopasty. The study included consecutive patients treated...

  • Should I Start Performing Nonpenetrating Glaucoma Surgery? Heuer, Dale K. // Ophthalmology Times;3/1/2006, Vol. 31 Issue 5, Special section p9 

    The article suggests the significance of a safe, effective predictable procedure to treat patients with glaucoma, citing the effects of patients' adherence to medical therapy for glaucoma. One effective procedure is the nonpenetrating glaucoma surgery, which has been perceived to produce lesser...

  • Eyes with damage to both hemifields show fastest glaucoma progression. Bechtel, Bryan; Boyle, Erin L.; Hasson, Matt // Ocular Surgery News;1/10/2010, Vol. 28 Issue 1, p16 

    The article gives information on eyes with damage to both hemifields show fastest glaucoma progression. A study was conducted that reveals patients with initial superior or inferior eye defect did not immediately experience glaucoma progression as easily as those with initial damage to both...

  • Clinical Experience in the Treatment of Normal Tension Glaucoma with Latanoprost in Germany. Thelen, Ulrich; Weiler, Winfried; Kirchhoff, Elisabeth; Fuchs, Heinz-Bernhard; Stewart, William C. // Journal of Ocular Pharmacology & Therapeutics;Jun2007, Vol. 23 Issue 3, p311 

    Aims: The aim of this analysis was to evaluate the general ophthalmologist's experience in using latanoprost to treat normal tension glaucoma (NTG) patients. Methods: NTG patients included in this study were part of an observational cohort of patients that were changed from previous therapy to...

  • Acute angle closure glaucoma (first report with irbesartan): case report.  // Reactions Weekly;7/16/2005, Issue 1060, p11 

    The article presents a case of a 42-year-old woman who developed acute angle closure glaucoma during treatment with irbesartan/hydrochlorothiazide. The patient exhibited various syndromes after she received the medicines. The medical history and condition of the patient were analyzed during the...

  • How Do You Know if a Patient Is Going Blind From Glaucoma? What Should You Do? Friedman, David S. // Ophthalmology Times;5/1/2005 Supplement, Vol. 30, p5 

    The article presents a discussion on glaucoma. Glaucoma is the second-leading cause of blindness worldwide. In population-based studies, when all the individuals in a community who have glaucoma are identified, the proportion that is actually blind at that moment ranges from about 3 percent to 5...

  • Feeling Comfortable With Fixed-Combination Agents.  // Ophthalmology Times;8/1/2009, Vol. 34 Issue 15, p25 

    The article discusses the application of fixed-combination therapies in glaucoma management. It cites the contribution of fixed-combination therapies to help practitioners to address the challenges and simplify the management of glaucoma. It also indicates the possibility of the therapies to be...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics